相关实验视频

Updated: Feb 20, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

翻译新兴数据用于胎儿治疗囊性纤维化

Michael V Zaretsky¹, Yair J Blumenfeld², Sylvia S Szentpetery³

¹Obstetrics and Gynecology, Division of Maternal Fetal Medicine University of Colorado School of Medicine, Aurora, Colorado, USA.

Prenatal diagnosis

|February 18, 2026

概括

囊性纤维化跨膜行为调节器治疗 (CFTRm) 在怀孕期间对患有CF的人来说是安全有效的,并且显示出治疗胎儿囊性纤维化 (CF) 在子宫中的前景,特别是麦科尼.

科学领域:

医学科学医学科学医学科学
药理学药理学是指药理学的学科.
遗传学是一个遗传学.

背景情况:

囊性纤维化转膜导电调节器疗法 (CFTRm) 是一种突破性的囊性纤维化 (CF) 治疗方法.
由于潜在的胎儿暴露,在怀孕期间使用它需要仔细考虑.
了解CFTRm在孕妇和胎儿的安全性和有效性至关重要.

研究的目的:

审查目前CFTRm在怀孕期间在CF患者的使用情况.
评估产前CFTRm对胎儿囊性纤维化 (CF) 的安全性和有效性,特别是麦科尼结膜 (MI).
确定有关产前CFTRm治疗的知识差距.

主要方法:

关于CFTRm在患有CF的孕妇中使用的当代文献的综述.
分析动物数据和已发表的人类病例的胎儿CFTRm对胎儿CF的分析.
检查结果,包括母亲的肺功能,产科结果和胎儿心脏病的结论.

主要成果:

在患有CF的孕妇中,CFTRm的延续与孕妇的肺功能和有利的产科结果的保持有关.
CFTRm穿过胎盘;动物对白内障的担忧没有在临床上观察到.
产前CFTRm在20例报告的胎儿病例中,大约三分之二的病例中解决了美结核 (MI),如果早些时候开始,结果会更好.

结论:

在怀孕期间,CFTRm似乎对母亲的使用是安全的,并显示出治疗胎儿疾病的潜力,如心脏病发作.
诊断和保险的延迟会影响产前CFTRm治疗的最佳时间.
需要对胎儿的药理动力学,安全性,剂量和戒断进行进一步的研究,以优化产前CFTRm使用.

更多相关视频

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

相关概念视频

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...